Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged myelodysplastic syndromes
What to make of Dr. Reddy’s IPR losses for Celgene’s Revlimid patent cases?

Last week, we wrote about milestones to watch for in Celgene’s ($CELG) Revlimid® patent landscape in 2019 that could potentially impact the Bristol Myers ($BMY) transaction.  One data-point that investors were anticipating were institution decisions in three petitions for inter partes review (IPRs) filed by Dr. Reddy’s.  This week, the PTAB denied institution of all three IPRs.  How will those decisions read-through to the overall Revlimid® patent landscape?

Read More
Markman AdvisorsCelgene, CELG, Bristol-Meyers Squibb, BMY, Revlimid, Inter Partes Review, patent, dr, lo, Lotus Pharmaceuticals, IPR, mds, myelodysplastic syndromes, mul, le, thalidomide, PTABComment
Why did Dr. Reddy’s file three IPRs against Celgene’s Revlimid patents?

On August 3, Dr. Reddy’s filed three petitions for inter partes review (IPR) against three patents owned by Celgene and listed in the Orange Book for Revlimid®.  Does this indicate that Celgene and Dr. Reddy’s are close to a settlement?  If not, what are the take-aways?

Read More
Markman AdvisorsCelgene, Dr. Reddy's, $CELG, Revlimid, Inter Partes Review, IPR, lenalidomide, MDS, myelodysplastic syndromes, Zachary Silbersher, Silbersher Comments